Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403686 · ClinicalTrials.gov registry record
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
A clinical trial of Diabetic Retinopathy, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 104
- Enrollment target
- 1
- Study location
NCT03403686 is a study of Diabetic Retinopathy that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 104 participants, below the 1,675-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03403686, a study of Diabetic Retinopathy, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to preserve the function of reparative cells while reducing inflammatory cell.
Conditions Studied
Interventions
- BIOLOGICAL blood draw
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03403686
The ClinicalTrials.gov registry entry for NCT03403686 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,675-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (94% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which blood draw is the first listed.
NCT03403686 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03403686 about?
NCT03403686 is a clinical study titled "Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)". Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X re...
What is the current status of trial NCT03403686?
This trial is currently recruiting. The enrollment target is 104 participants. The study started on 2018-01-11. Estimated completion is 2026-12-31.
What conditions does trial NCT03403686 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT03403686?
The interventions under investigation include: blood draw (BIOLOGICAL).
Who is sponsoring clinical trial NCT03403686?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03403686 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.